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Abstract
Refractory Anemia with Ring Sideroblasts (RARS) is an acquired myelodysplastic syndrome (MDS) characterized by an excess
iron accumulation in the mitochondria of erythroblasts. The pathogenesis of RARS and the cause of this unusual pattern of
iron deposition remain unknown. We considered that the inherited X-linked sideroblastic anemia with ataxia (XLSA/A) might
be informative for the acquired disorder, RARS. XLSA/A is caused by partial inactivating mutations of the ABCB7 ATP-binding
cassette transporter gene, which functions to enable transport of iron from the mitochondria to the cytoplasm.
Furthermore, ABCB7 gene silencing in HeLa cells causes an accumulation of iron in the mitochondria. We have studied the
role of ABCB7 in RARS by DNA sequencing, methylation studies, and gene expression studies in primary CD34
+ cells and in
cultured erythroblasts. The DNA sequence of the ABCB7 gene is normal in patients with RARS. We have investigated ABCB7
gene expression levels in the CD34
+ cells of 122 MDS cases, comprising 35 patients with refractory anemia (RA), 33 patients
with RARS and 54 patients with RA with excess blasts (RAEB), and in the CD34
+ cells of 16 healthy controls. We found that
the expression levels of ABCB7 are significantly lower in the RARS group. RARS is thus characterized by lower levels of ABCB7
gene expression in comparison to other MDS subtypes. Moreover, we find a strong relationship between increasing
percentage of bone marrow ring sideroblasts and decreasing ABCB7 gene expression levels. Erythroblast cell cultures
confirm the low levels of ABCB7 gene expression levels in RARS. These data provide an important link between inherited and
acquired forms of sideroblastic anemia and indicate that ABCB7 is a strong candidate gene for RARS.
Citation: Boultwood J, Pellagatti A, Nikpour M, Pushkaran B, Fidler C, et al (2008) The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring
Sideroblasts. PLoS ONE 3(4): e1970. doi:10.1371/journal.pone.0001970
Editor: Mikhail V. Blagosklonny, Ordway Research Institute, United States of America
Received January 24, 2008; Accepted March 5, 2008; Published April 9, 2008
Copyright:  2008 Boultwood et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Leukaemia Research Fund of the UK, and in part by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro),
Milan, and Fondazione IRCCS Policlinico San Matteo, Pavia, to M.C.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jacqueline.boultwood@ndcls.ox.ac.uk
. These authors contributed equally to this work.
Introduction
The myelodysplastic syndromes (MDS) are a heterogeneous
group of hematopoietic malignancies, characterized by blood
cytopenias, ineffective hematopoiesis and a hypercellular bone
marrow [1]. Refractory Anemia with Ring Sideroblasts (RARS) is
a subtype of MDS in which excess iron accumulates in the form of
aberrant mitochondrial ferritin in the mitochondria of the
erythroid precursors [2,3]. RARS is a myeloid malignancy and
transforms to acute leukemia in approximately 10–20% of cases
[4]. The molecular genetic basis of RARS remains unknown.
The hereditary sideroblastic anemias are a heterogeneous group
of disorders characterized by the presence of ring sideroblasts in
the bone marrow, microcytic hypochromic anemia and typically
show X-linked inheritance [5–7]. Many of the reported cases of
inherited X-linked sideroblastic anemia have been found to be
caused by mutations in the erythroid-specific delta-aminolevuli-
nate synthase gene (ALAS2) [8]. A rare inherited X-linked
sideroblastic anemia with ataxia (XLSA/A) is caused by mutations
of the mitochondrial ATP-binding cassette transporter ABCB7
[9,10]. The ABCB7 gene is the functional orthologue of the yeast
Atm1p gene [11], which is required for mitochondrial iron
homeostasis [12] and has been implicated in the transport of a
component required for the maturation of iron-sulfur (Fe-S) cluster
proteins out of mitochondria [13]. It has been demonstrated that
XLSA/A is due to partial loss of function mutations in ABCB7 that
directly or indirectly inhibit heme biosynthesis [13]. The anemia
in XLSA/A is caused by the accumulation of iron in a form that is
not readily usable for heme synthesis [14]. Moreover, ABCB7 has
been demonstrated to be essential for hematopoiesis in experi-
ments using conditional gene targeting in mice [13]. In an
important experiment, ABCB7 has been silenced in HeLa cells by
sequential transfection experiments with siRNAs [14]. The
phenotype of the ABCB7-deficient cells was characterized by a
reduction in proliferation rate that was not rescued by iron
supplementation, by signs of iron deficiency, and by a large
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available to mitochondrial ferritin.
We have investigated the expression levels of the ABCB7 gene
using data from our large microarray dataset on CD34
+ cells from
MDS patients and healthy controls in order to determine whether
the ABCB7 gene is implicated in the common acquired
sideroblastic anemia, RARS.
Materials and Methods
Sample collection and cell separation
122 patients with MDS and 16 healthy controls were included
in the study. Classification of MDS patients was according to the
French-American-British (FAB) criteria [15] and the patients were
selected solely on the basis of having MDS. The MDS patient
samples were obtained from several sources: Oxford, Bourne-
mouth and Dundee (United Kingdom), Stockholm (Sweden),
Duisburg (Germany) and Pavia (Italy). At the time of investigation,
35 patients had Refractory Anemia (RA), 33 RARS and 54
Refractory Anemia with Excess Blasts (RAEB). The study was
approved by the ethical committees of the John Radcliffe Hospital
(Oxford), the Karolinska Institutet (Stockholm), the IRCCS
Policlinico S. Matteo (Pavia), the Royal Bournemouth Hospital
(Bournemouth), the St Johannes Hospital (Duisburg) and the
Ninewells Hospital (Dundee); written informed consent was
obtained from study participants. CD34
+ cells were isolated from
the bone marrow samples of MDS patients and healthy controls
using MACS magnetic cell separation columns (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufacturer’s
recommendations.
Erythroblast cell cultures
CD34
+ cells isolated from the bone marrow of 8 patients with
RARS, 9 patients with RA and 8 healthy controls were cultured
according to a method developed to study the generation of
erythroblasts [16,17]. Gene expression profiling experiments were
performed on cultured cells at day 7.
Microarray experiments and data analysis
Gene expression profiling experiments and data analysis were
performed as previously described [18]. Affymetrix GeneChip
Human Genome U133 Plus 2.0 arrays (47,000 transcripts) were
used. Gene correlations were calculated using Pearson correlation.
Real-time quantitative PCR
Real-time quantitative PCR for the ABCB7 gene was performed
using cDNA made from the unamplified RNA from CD34
+ cells
of 7 patients with RARS, 8 patients with RA, 6 patients with
RAEB and 7 healthy controls. Beta-2-microglobulin was used to
normalize for differences in input cDNA. Reactions were
performed as previously described [16] and expression ratios were
calculated using the DDCT method [19].
Statistical analysis
Statistical analysis and box plots were created using StatView
software. Kruskal-Wallis test was used for comparison between three
or more groups and Mann-Whitney U test for comparisons between
any two groups. A P-value ,0.01 was considered significant.
DNA sequencing
Direct sequencing of ABCB7 was performed on DNA from 13
RARS patients using Applied Biosystems Big dye terminator kit
v1.1.
Promoter methylation studies
We looked at promoter methylation of ABCB7 in DNA samples
from 6 RARS patients (2 bone marrow, 2 neutrophil and 2 CD34
+
samples) and from 5 healthy controls (1 bone marrow, 1
neutrophil, 1 mononuclear cell and 2 CD34
+ samples). The
ABCB7 promoter was predicted using PromoterScan and CpGPlot
software. For investigation of methylation status we used bisulphite
sequencing. Bisulphite modification of the genomic DNA was
carried out using the EpiTect Bisulphite kit (Qiagen). Primers to
amplify the modified DNA for bisulphite sequencing were
designed using Primer3 software and were as follows: 59-
GTTTGGGGTTTTGGGAAAAT-39 (ABCB7 forward primer)
and 59-TTCCATATCAATAACATCTCACCTAA-39 (ABCB7
reverse primer). The PCR products were purified with the Wizard
PCR Clean-Up System and Vacuum Manifold (Promega,
Madison, WI) according to the manufacturer’s instructions. PCR
products were cloned using the pGEM-T Easy cloning system
(Clontech) and sequenced with Applied Biosystems Big dye
terminator kit v1.1 and the ABCB7 forward primer.
Results
ABCB7 expression levels in MDS subtypes
We have determined the ABCB7 gene expression levels from our
microarray dataset on CD34
+ cells in 122 MDS patients and 16
healthy controls. We have compared the gene expression levels of
ABCB7 between 35 patients with refractory anemia (RA), 33
patients with RARS, 54 patients with RA and excess blasts
(RAEB), and 16 healthy controls (Table 1; Figure 1A). The
expression levels of ABCB7 are lowest in the RARS group
compared to RA (p,0.0001), RAEB (p,0.0001) and healthy
controls (p,0.0001). No significant difference was observed
between the RA, RAEB and healthy control groups.
ABCB7 expression levels and percentage of bone marrow
ring sideroblasts
The 101 of 122 MDS cases, where data was available on the
exact percentage of bone marrow ring sideroblasts, have been
divided in three groups by percentage of bone marrow ring
sideroblasts (0–14%, 15–40% and .41%) (Table 1; Figure 1B). It
can be seen that the median expression level of ABCB7 falls
progressively across the three groups. As shown in Table 1, the
differences in ABCB7 expression between the three groups are all
statistically significant.
ABCB7 expression levels in erythroblast cultures
In addition, we have studied the ABCB7 gene expression levels in
erythroblast cultures derived from the CD34
+ cells of 8 patients with
RARS, 9 patients with RA and 8 healthy controls. Cells were
cultured according to a method developed to study the generation of
erythroblasts[16,17]andgeneexpressionprofilingexperimentswere
performed on cultured cells at day 7. We confirmed the low levels of
ABCB7 gene expression levels in RARS erythroblasts in comparison
to those of RA and healthy controls (Table 1; Figure 1C).
Confirmation of ABCB7 expression data
The microarray-generated expression data of the ABCB7 gene
were validated and confirmed in a subset of 21 MDS patients (7
patients with RARS, 8 patients with RA, 6 patients with RAEB)
and 7 healthy controls using real-time quantitative PCR (Figure 2).
A high concordance was observed between the expression levels
obtained with Affymetrix chips and with real-time quantitative
PCR, indicating a good level of agreement between the two assays.
Role of ABCB7 in RARS
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Direct sequencing of ABCB7, including the promoter region,
was performed on DNA from 13 RARS patients and did not show
any mutations in any of the patients. We have investigated the
methylation status of the ABCB7 promoter region in 6 patients
with RARS and 5 healthy controls, and the results showed .80%
methylation in all samples, with no significant difference between
RARS patients and healthy controls.
ABCB7 gene correlation
No genomic abnormality in the ABCB7 gene was identified in
our cases. Therefore, we examined our microarray dataset for
genes with expression levels correlated either strongly positively
($0.8) or inversely (#20.8) with ABCB7 gene expression levels.
The expression of two genes showed a positive correlation with
ABCB7 expression: ELP2 (0.82) and RTF1 (0.80). No genes were
found whose expression correlated inversely with ABCB7.
Figure 1. ABCB7 expression levels. (A) ABCB7 expression levels in the CD34
+ cells from healthy controls and MDS patients with RA, RAEB and
RARS. (B) ABCB7 expression levels and percentage of ring sideroblasts in the bone marrow. (C) ABCB7 expression levels in cultured erythroblasts from
healthy controls and MDS patients with RA and RARS. The boxes represent the 25
th,5 0
th and 75
th percentiles, the bars correspond to the 10
th and
90
th percentiles.
doi:10.1371/journal.pone.0001970.g001
Table 1. Descriptive statistics of ABCB7 expression levels in CD34
+ cells according to FAB group, in CD34
+ cells according to
percentage of bone marrow ring sideroblasts, and in cultured erythroblasts at day 7.
CD34
+ CELLS - FAB MEAN STD DEV Kruskal-Wallis p,0.0001
Controls (n=16) 0.98 0.36 Controls RA RAEB
RA (n=35) 0.88 0.34 RA 0.3610 — —
RAEB (n=54) 0.94 0.44 RAEB 0.5476 0.7211 —
RARS (n=33) 0.49 0.19 RARS ,0.0001 ,0.0001 ,0.0001
% SIDEROBLASTS MEAN STD DEV Kruskal-Wallis p,0.0001
0–14 (n=57) 1.03 0.39 0–14 15–40
15–40 (n=26) 0.62 0.26 15–40 ,0.0001 —
41+ (n=18) 0.42 0.07 41+ ,0.0001 0.0022
DAY 7 ERYTHROBLASTS MEAN STD DEV Kruskal-Wallis p=0.0001
Controls (n=8) 1.05 0.11 Controls RA
RA (n=9) 0.73 0.24 RA 0.0071 —
RARS (n=8) 0.34 0.08 RARS 0.0008 0.0021
doi:10.1371/journal.pone.0001970.t001
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We have examined the role of ABCB7, the gene involved in the
hereditary XLSA/A, in the acquired RARS syndrome. The
hypothesis under consideration is that XLSA/A and acquired
RARS may have a shared molecular basis. Interestingly, there is
an excess of erythrocyte protoporphyrin in XLSA/A (in contrast
with other types of genetic sideroblastic anemia) as also found in
RARS [20]. We have determined the ABCB7 gene expression
levels from our microarray dataset on CD34
+ cells in 122 MDS
patients and 16 healthy controls. The expression levels of ABCB7
are significantly lower in the RARS group than in healthy
controls, RA or RAEB. In contrast there is no significant
difference in ABCB7 expression between the latter three groups.
The definition of RARS includes more than 15% ring
sideroblasts in the bone marrow. However, we find not only
lower levels of ABCB7 in RARS than other MDS but also a
progressive reduction of ABCB7 expression as the percentage of
ring sideroblasts increases. In addition, we have studied the ABCB7
gene expression levels in erythroblast cultures and confirmed the
low levels of ABCB7 gene expression levels in RARS erythroblasts
in comparison to those of RA and healthy controls.
The gene expression levels of ABCB7 were validated and
confirmed in a subset of MDS patients and healthy controls using
real-time quantitative PCR. Direct sequencing of ABCB7,
including the promoter region, was performed on DNA from 13
RARS patients and did not show any mutations in any of the
patients. Similarly, Steensma et al, in a recent study, found no
coding mutations of ABCB7 in patients with RARS [20].
We have investigated the methylation status of the ABCB7
promoter region and the results showed .80% methylation in all
samples, with no significant difference between RARS patients
and healthy controls. Gene promoters can be divided into three
groups according to their CpG ratio, GC content and length of
CpG-rich region: high-CpG, intermediate-CpG and low-CpG
promoters [21]. Based on this classification, the ABCB7 promoter
region is defined as an intermediate-CpG promoter. Intermediate-
CpG promoters show a high frequency of DNA methylation [21].
Our data fit with the definition of the ABCB7 promoter region as
an intermediate CpG promoter, but suggest that promoter
methylation is unlikely to be the mechanism underlying the
reduction in expression levels of ABCB7 observed in RARS.
No genomic abnormality in the ABCB7 gene was identified in
our cases, suggesting that there could be a trans-acting factor
responsible for the low levels of ABCB7 in RARS (analogous to the
down regulation of the alpha-globin genes in the acquired HbH
associated with MDS caused by mutations in the ATRX gene) [22].
Therefore, we examined our microarray dataset for genes with
expression levels correlated either strongly positively ($0.8) or
inversely (#20.8) with ABCB7 gene expression levels. While no
other gene had a strong inverse correlation with ABCB7,
interestingly two genes showed a positive correlation: ELP2
(0.82) and RTF1 (0.80), both of which are associated with RNA
Polymerase II [23,24]. Deregulation of these factors may cause
defective gene transcription through chromatin [25].
The existence of an inherited disorder XLSA/A caused by
inactivating mutations in ABCB7 is, of course, very informative of
the probable consequences of reduced expression of the same gene
in acquired disorders. Many of the key properties of ABCB7 have
already been established by gene silencing studies and by
conditional gene targeting in mice [13,14]. All of these
experiments are consistent with the importance of ABCB7 in
hematopoiesis and with the observed phenotype in XLSA/A.
Therefore, it would be predicted that erythroblasts with low
ABCB7 levels would have abnormal mitochondrial iron homeo-
stasis. Our finding of a strong association between RARS and low
gene expression levels of ABCB7 also raises the possibility of
therapeutic approaches for RARS using drugs which induce the
expression of ABCB7, for example, carbamazepine has been
shown to induce ABCB7 in the liver of epileptic patients treated
with the drug [26]. We suggest that down-regulation of the iron
transporter ABCB7 plays an important role in the molecular
pathogenesis of RARS, making an intriguing link between the
inherited and acquired forms of sideroblastic anemia.
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